This article addresses the three contamination control challenges that are specific to the CDMO environment, provides five practical steps any organization can act on now, and more.
- Rethinking CQV In A Digital, Agile Manufacturing Landscape
- Will FDA's One-Day Inspection Pilot Stand The Test Of Time?
- A Multi-Agent Audit Intelligence Framework For CDMO Quality Oversight
- Why Contamination Control By Design Should Matter To Your CDMO
- Repeating Sanofi's Ballroom Design On Two Continents
- Closing The MES Value Gap: Why Technology Isn't The Problem
- Why Are Life Science Companies So Poorly Prepared For RIM's Future?
GUEST COLUMNISTS
-
Rethinking CQV In A Digital, Agile Manufacturing Landscape
While commissioning, qualification, and validation (CQV) remains foundational, the way it is planned and executed must evolve to keep pace with modern manufacturing realities.
-
Will FDA's One-Day Inspection Pilot Stand The Test Of Time?
FDA's complementary pilot could help weed through a persistent examination backlog, but uncertainty and upheaval in leadership at the top puts its future in question.
-
A Multi-Agent Audit Intelligence Framework For CDMO Quality Oversight
A Takeda quality executive demonstrates how a team of AI agents uses synthetic data to provide decision support ahead of CDMO audits.
-
Why Contamination Control By Design Should Matter To Your CDMO
EU GMP Annex 1 mandates a documented contamination control strategy, and FDA expectations are substantively equivalent. Let's look at why CDMOs are disproportionately exposed.
-
Repeating Sanofi's Ballroom Design On Two Continents
Moveable walls and a stunning number of robotics at its sites in France and Singapore, among other features, has earned Sanofi international recognition for innovation.
-
Closing The MES Value Gap: Why Technology Isn't The Problem
Manufacturing execution system (MES) technical maturity is rising, but adoption across manufacturing sites is uneven. Organizational readiness may hold the key.
-
Why Are Life Science Companies So Poorly Prepared For RIM's Future?
Most organizations have modernized their global regulatory information management (RIM) systems and improved data quality. Yet modernization and readiness are not the same thing.
BIOSIMILAR WHITE PAPERS
-
Economic Advantage Of Robotic Gloveless Pharmaceutical Isolators
Are robotic gloveless isolators the key to smarter, safer, scalable solutions? Discover how they can revolutionize aseptic filling by reducing contamination, minimizing waste, and enhancing manufacturing flexibility.
-
Bio-Based Polymers Towards Net Zero In Single-Use Bioprocessing6/13/2025
Decarbonizing healthcare and pharmaceuticals is vital to meet climate goals and safeguard public health. Learn why these energy-intensive sectors must act swiftly to reduce emissions and navigate complex global supply chains.
-
Why Choose Robotic Processing For Small Batch Aseptic Filling1/9/2026
Reducing human intervention in aseptic filling is critical for safety and cost efficiency. Learn why automation is essential for small-batch applications and how it’s transforming sterile drug manufacturing.
-
Digital Biomanufacturing, Now: From Digital Dreamer To Digital Doer3/24/2025
Discover how digital biomanufacturing is revolutionizing drug production by exploring strategies for integrating digital technologies to enhance efficiency and innovation in bioprocessing workflows.
-
Revolutionizing Drug Discovery From "Undruggables" To AI6/10/2024
Explore four current trends in drug discovery, how each trend addresses some of the most crucial challenges in drug discovery, and the obstacles to their widespread adoption.
-
Biopharma Supply, Reimagined: Regional, Resilient Manufacturing4/1/2026
Persistent disruption is redefining biopharma supply chains. Explore how regional manufacturing, integrated risk management, and closer collaboration help build resilience and improve agility.
BIOSIMILAR APP NOTES & CASE STUDIES
- Packing MabSelect™ And MabSelect SuRe™ Resins Using Verified Methods
- Microbial Integrity Of Sampling Systems After Multiple Actuations
- mRNA Manufacturing With Fed-Batch In Vitro Transcription
- TFF Cassettes With 100 kDa Membranes For RNA And LNP Applications
- Implementation Of Multi-Column Chromatography Systems
BIOSIMILAR DEVELOPMENT CONTENT COLLECTIONS
The debate over whether the biosimilar regulatory paradigm can shift away from comparative efficacy trials has intensified over the past few years. This collection of articles serves as a snapshot of the many different components of this ongoing discussion.
More Content CollectionsBIOSIMILAR DEVELOPMENT NEWS
- Globalisation 2.0 | First Patient Dosed In China For International Multi-Centre Phase 1 Clinical Trial Of Henlius' Subcutaneous Daratumumab Biosimilar HLX15-SC
- Polpharma Biologics And Tuteur Sign Licensing Agreement For A Biosimilar For Autoimmune Diseases
- Mabwell Announces NMPA Approval Of Supplemental Application For Additional Indications Of MAIWEIJIAN (Denosumab Injection)
- Dr. Reddy's Laboratories Announces Launch Of Oral Semaglutide Biosimilar 'Obeda' (Tablets) In India
- Formycon Expands Commercial Portfolio: Aflibercept Biosimilars Ahzantive And Baiama Are Now Available In The European Union
- Samsung Bioepis Launches Ustekinumab Biosimilar, Marking Its First Product Launch In Japan
- FDA Approves IMMGOLIS™ (golimumab-sldi) And IMMGOLIS INTRI™ (golimumab-sldi), First Biosimilars To Simponi® (golimumab) And Simponi Aria® (golimumab); Accord BioPharma To Lead U.S. Commercialization
- MS Pharma Announces Strategic Growth Investment From Olayan Financing Company
NEWSLETTER ARCHIVE
- 05.21.26 -- Minimizing Regulatory Risk For Biologics Manufacturing Changes
- 05.14.26 -- Do Changes Signal The End Of Biosimilar Regulatory Redundancy?
- 05.07.26 -- The Business Case For Continuous Manufacturing In Biologics
- 04.30.26 -- Quantifying Single-Use Waste Produced During mAb Manufacture
- 04.16.26 -- Innovation That's Redefining Aseptic Filling